Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Primary Hyperoxaluria Type 1 (PH1)
Clinical trial register · Germany

Primary Hyperoxaluria Type 1 (PH1) Trials in Germany, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5081 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:18 UTC
5081
Studies in scope
all four open statuses
2880
Recruiting now
open to new participants
985
Lead sponsors
across recruiting studies
Top sites
Bonn 2 Heidelberg 1
Narrow the registerReset
Recruitment status
Phase
Site location
Bonn2 Heidelberg1
All 2 locations
Target enrolment
to

Primary Hyperoxaluria Type 1 (PH1) trials in Germany

2 of 5081 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
NCT06839235Primary Hyperoxaluria Type 1 (PH1)
Arbor Biotechnologies
Phase 1/2
23
Bonn
2025-06-16
Active, closed
Long Term Extension Study in Patients With Primary Hyperoxaluria
NCT04042402Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase 3
75
Bonn, Heidelberg
2019-07-09
Rows per page Showing 1–2 of 2
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 November 2026. https://priyalifescience.com/clinical-trials-germany/condition/primary-hyperoxaluria-type-1-ph1

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,081 studies in total at the last sync on 13 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2 of those studies listing the condition Primary Hyperoxaluria Type 1 (PH1).

How many Primary Hyperoxaluria Type 1 (PH1) trials are recruiting in Germany?

1 of the 2 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Primary Hyperoxaluria Type 1 (PH1)), 2 studies
PhaseStudiesRecruitingShare
Phase 1/21150%
Phase 31050%

Most active sponsors

Lead sponsors with the most studies (Primary Hyperoxaluria Type 1 (PH1))
Lead sponsorStudiesRecruiting
Arbor Biotechnologies11
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.